Environmental exposures, including cannabis, and lung cancer
Environment and Lung Cancer
Adults with primary lung cancer aged 18–59 will give blood and hair samples so researchers can try to link cannabis use and other environmental exposures to the cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 59 Years |
| Sex | All |
| Sponsor | Centre Chirurgical Marie Lannelongue Academic / other |
| Locations | 3 sites (Le Plessis-Robinson and 2 other locations) |
| Trial ID | NCT05119244 on ClinicalTrials.gov |
What this trial studies
This project collects blood and hair samples from patients aged 18–59 treated for primary lung cancer at three French hospitals to measure markers of cannabis exposure and other environmental carcinogens. Samples will be analyzed to quantify toxic compounds and reconstruct exposure histories alongside clinical data. The work responds to mixed prior evidence: toxicology shows high concentrations of carcinogens in cannabis smoke while epidemiology has been largely reassuring. By adding biomarker data from treated patients, the study aims to clarify possible relationships between cannabis exposure and lung carcinogenesis.
Who should consider this trial
Good fit: Adults aged 18 to 59 treated for primary lung cancer at one of the participating hospitals who agree to participate are eligible.
Not a fit: People older than 59, those not treated at the listed hospitals, or those who do not consent would not be eligible and therefore would not benefit from participation.
Why it matters
Potential benefit: If successful, the study could improve understanding of whether cannabis exposure contributes to lung cancer and help guide prevention advice and patient counseling.
How similar studies have performed: Previous human studies have generally not shown a clear link between cannabis smoking and lung cancer while laboratory analyses find higher carcinogen concentrations in cannabis smoke, so human biomarker data remain limited and this approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient from 18 y.o to 59 y.o treated in one of the three above-mentioned hospitals for primary lung cancer, whatever its stage, and agreeing to participate in this research. Exclusion Criteria: * Patient denied participation.
Where this trial is running
Le Plessis-Robinson and 2 other locations
- Centre Chirurgical Marie Lannelongue — Le Plessis-Robinson, France (Recruiting)
- Hopital Paris Saint Joseph — Paris, France (Completed)
- Institut Gustave Roussy — Villejuif, France (Completed)
Study contacts
- Study coordinator: Pauline PRADERE, MD
- Email: p.pradere@ghpsj.fr
- Phone: 01.40.94.22.79
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.